Related Experiment Video
Updated: Jul 24, 2025

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
Robert Nunn1, Anne Sylvestre1, Kelly Sequeira1
1St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
Objectives:
To describe the use of buprenorphine/naloxone micro-inductions in hospitalized patients and characterize the success rate of these inductions.
Methods:
We conducted a retrospective chart review of hospitalized patients receiving a buprenorphine/naloxone micro-induction for opioid use disorder in a tertiary care hospital from Jan 2020-Dec 2020. The primary outcome was a description of the micro-induction prescribing patterns used. The secondary outcomes were a description of the demographic characteristics of patients, the estimated frequency of withdrawal symptoms experienced by patients undergoing a micro-induction, and the overall success rate of the micro-inductions defined as retention on buprenorphine/naloxone therapy with no precipitated withdrawal experienced.
Results:
Thirty-three patients were included in the analysis. Three main micro-induction regimens were identified, including rapid micro-inductions (8 patients), 0.5 mg SL BID initiations (6 patients), and 0.5 mg SL daily initiations (19 patients). Twenty-four patients (73%) met the criteria for a successful micro-induction, defined as being retained in buprenorphine/naloxone therapy with no precipitated withdrawal experienced. The most common reason for micro-induction failure was patient request to discontinue buprenorphine/naloxone therapy due to perceived adverse effects or personal preference.
Conclusion:
Buprenorphine/naloxone micro-induction in hospitalized patients resulted in a majority of patients being successfully initiated on buprenorphine/naloxone therapy without requiring opioid abstinence prior to induction. Dosing regimens were variable, and the ideal regimen remains unclear.
Insights
Buprenorphine/naloxone micro-inductions successfully initiated 73% of hospitalized patients with opioid use disorder without prior abstinence. Variable dosing regimens were observed, indicating further research is needed for optimal treatment protocols.
Area of Science:
- Addiction Medicine
- Pharmacology
Background:
- Opioid use disorder (OUD) is a significant public health crisis.
- Hospitalized patients with OUD often face challenges in initiating medication for addiction treatment (MAT).
- Buprenorphine/naloxone is a key medication for OUD treatment, but induction can be complex.
Purpose of the Study:
- To describe the utilization and success rates of buprenorphine/naloxone micro-inductions in an inpatient setting.
- To characterize prescribing patterns and patient outcomes associated with micro-induction protocols.
Main Methods:
- Retrospective chart review of 33 hospitalized patients receiving buprenorphine/naloxone micro-inductions for OUD.
- Analysis of prescribing patterns, patient demographics, withdrawal symptom frequency, and treatment success.
- Success defined as retention on therapy without precipitated withdrawal.
Main Results:
- Three primary micro-induction regimens were identified: rapid, 0.5 mg SL BID, and 0.5 mg SL daily.
- 73% of patients (24/33) achieved successful micro-induction.
- The main reason for failure was patient-initiated discontinuation due to adverse effects or preference.
Conclusions:
- Buprenorphine/naloxone micro-induction is an effective strategy for initiating MAT in hospitalized patients, often without requiring prior opioid abstinence.
- Observed variability in micro-induction dosing regimens suggests a need for further investigation into optimal protocols.
- This approach facilitates timely OUD treatment initiation during hospitalization.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Receptors: Overview
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Dependence

